Hyperthermia in the Gorter Model – A Significant Part of the Cancer Treatment
We know scientifically that fever is a protective mechanism. When body temperature reaches 101.3° F (38.5° C) the immune system shifts into a state of alarm. At this temperature, the level of immune chemicals in the bloodstream doubles and immune defenses throughout the body increase. Within six hours, almost every major defense within the immune system doubles its efforts. This process appears to be dormant in many cancer patients, who typically report never having experienced a fever. To reactivate the immune system in these patients, the Gorter Model uses a process of controlled fever referred to in the scientific literature as “fever-range, total-body hyperthermia”—a form of treatment in which the entire body is heated to a moderate fever temperature of approximately 101.3 F (38.5 C). As a result, the immune system is activated in the same way as a natural fever would activate immune response, for example to an infection. This approach is necessary to raise the body to a therapeutic fever range, unlike traditional methods such as sauna methods and hot tub, which do not affect core temperature or achieve temperatures that are as high as the temperature range that occurs during a fever. In the Gorter Model, total-body hyperthermia is provided to about 70% of all patients. Local hyperthermia is another approach used in the Gorter Model. Localized heat is applied to the tumor tissue; a “region” or area of the body is selectively heated, again so that only the cancer cells increase in temperature. The local heating increases the temperature within the the malignant cells to 42 C (107.6 F) so that they die, due to the increased intra-cellular lactic acid production.Only the cancer cells are increased in temperature which leads directly to cell death (necrosis). The localized high temperature and the resulting cancer cell death also activates the immune system. The surrounding healthy cells are not affected. Local hyperthermia is used with approximately 99% of patients.